TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30911656
Drug: Pressurized IntraPeritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Study: 30911663
Drug: PIPAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC with oxaliplatin (starting dose 45 mg/m)
Study: 30911664
Drug: Oxaliplatin administered
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin administered by the intraperitoneal route (PIPAC) at a starting dose of 90 mg/m², during two consecutive procedures at a 4-6 week interval.
Study: 30911664
Drug: High-dose oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxaliplatin during PIPAC
Study: 30911859
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + chemotherapy (200 mg on day 1, cisplatin 80 mg/m)
Study: 30911859
Drug: Pembrolizumab (monotherapy)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (monotherapy)
Study: 30911926
Drug: Extended-pulsed fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended-pulsed fidaxomicin (EPFX) 200 mg twice daily (days 1-5); once daily on alternate days (days 7-25)
Study: 30911926
Drug: Vancomycin 125
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 125 mg four times daily (days 1-10)
Study: 30913032
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue (SAT) distribution measurements at 15 standardized locations
Study: 30913226
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension 12 mg/kg/day BID
Study: 30913226
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension 18 mg/kg/day TID
Study: 30913226
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension 18 mg/kg/day BID
Study: 30913226
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension 12 mg/kg/day BID, 18 mg/kg/day BID, and 18 mg/kg/day TID
Study: 30913226
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension
Study: 30914274
Drug: FSH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH treatment (3-6 hours)
Study: 30914274
Drug: Elevated FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated FSH (>11 U/L) in infertile men
Study: 30914970
Drug: Novel nutraceutical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel nutraceutical compound containing red yeast rice, polymethoxyflavones, and antioxidants, dosage and duration not available
Study: 30915029
Drug: Acipimox administration
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox administration with exercise
Study: 30915112
Drug: Preoperative TG
Normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative TG levels in benign group (median 167.5 ng/mL)
Study: 30915626
Drug: Phosphate-free formulation
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate-free formulation of etanercept (50 mg)
Study: 30915626
Drug: Prior formulation
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior formulation of etanercept (50 mg)
Study: 30915922
Drug: Atezolizumab (TECENTRIQ®)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (TECENTRIQ®) plus chemotherapy (Abraxane; nab®-Paclitaxel)
Study: 30915992
Drug: High-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose i.v. naloxone infusion (total dose 3.25 mg kg)
Study: 30917689
Drug: Subcutaneous implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous implantable cardioverter-defibrillator shock at 65 J
Study: 30917871
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interleukin-2 (HD IL-2)
Study: 30917871
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interleukin-2 (HD IL-2) alone
Study: 30918874
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of insulin doses normalized for body weight
Study: 30920187
Drug: Current opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current opioid agonist treatment (buprenorphine maintenance)
Study: 30921081
Drug: Apical suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical suspension
Study: 30921081
Drug: No apical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No apical suspension
Study: 30922248
Drug: Icaritin 600
Normalized name: Icariin
DrugBank: Icariin (DB12052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icaritin 600 or 800 mg b.i.d.
Study: 30922276
Drug: Enemas, methylnaltrexone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enemas, methylnaltrexone, or 4-l polyethylene-glycol solution
Study: 30922276
Drug: Morphine equivalent
Normalized name: paregoric 2 MG (as morphine equivalent) in 5 mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine equivalent daily dose
Study: 30922805
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pertuzumab, subcutaneous trastuzumab, and taxane chemotherapy
Study: 30923464
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 μg/day) and Coenzyme Q10 (200 mg/day)
Study: 30923820
Drug: anti-PD-1 therapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 therapy (pembrolizumab or nivolumab)
Study: 30924406
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccines (PCVs) - ≥1 dose ≥ age 2 months
Study: 30924924
Drug: BRV (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV (100 mg, intravenous)
Study: 30924924
Drug: BRV (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV (200 mg, intravenous)
Study: 30924924
Drug: LEV (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV (1500 mg, intravenous)
Study: 30924924
Drug: BRV (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV (50-100 mg, oral, twice-daily for 4 days)
Study: 30924924
Drug: LEV (250-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV (250-600 mg, oral, 4 hours postdose)
Study: 30924938
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 6'6'H2 glucose
Study: 30926081
Drug: Decitabine 30
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 30 mg plus cedazuridine 100 mg
Study: 30926081
Drug: Decitabine 40
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 40 mg plus cedazuridine 100 mg
Study: 30927064
Drug: Higher-dairy diets
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dairy diets (Q4, 274-1429 g/day dairy)
Study: 30928173
Drug: FSME-IMMUN vaccination
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSME-IMMUN vaccination after 3-dose primary immunization
Study: 30928393
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of age, BMI, PlGF, and MMP9 for OSA identification
Study: 30929188
Drug: Blephapad Combo
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blephapad Combo treatment arm (wet wipes with terpinen-4-ol and hyaluronic acid)
Study: 30929188
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment arm (wet and warm gauze)
Study: 30929188
Drug: Blephapad Combo
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blephapad Combo treatment arm
Study: 30929225
Drug: Medical exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical exercise therapy for 3 months
Study: 30929678
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 22.5-mg depot
Study: 30929749
Drug: WHO 2015
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO 2015 guidelines for treatment eligibility
Study: 30929749
Drug: EASL 2017
Approvals — FDA: no, EMA: no, PMDA: no
Description: EASL 2017 guidelines for treatment eligibility
Study: 30930133
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Insulin (RI) on TPN
Study: 30930133
Drug: Glargine Insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine Insulin (GI)
Study: 30932132
Drug: Participants meeting
Normalized name: Dolce and Gabbana Meet Your Flawless Matte Skin Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants meeting the protein recommendation (0.8 g/kg/d)
Study: 30932132
Drug: Participants not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants not meeting the protein recommendation (0.8 g/kg/d)
Study: 30935383
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present.
Study: 30935734
Drug: Anti-TNFα therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNFα therapy
Study: 30936830
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Ticagrelor, dosage not specified, duration not specified
Study: 30937138
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) drops containing tree pollen allergens (ORALVAC) with a rapid home-based up-dosing schedule
Study: 30937138
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) drops containing tree pollen allergens (ORALVAC)
Study: 30937138
Drug: Pre-seasonal treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-seasonal treatment initiation with SLIT
Study: 30938688
Drug: Interactive Voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Voice Response and Text Message (IVR-T) intervention including automated text messages or phone calls in English or Spanish, reminders for appointments, medication refills, and motivational messages; offered home blood pressure monitor.
Study: 30938714
Drug: Conditioning chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning chemotherapy followed by CD19-targeted CAR T-cells (19-28z).
Study: 30938714
Drug: Ibrutinib therapy
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib therapy at the time of autologous T-cell collection and/or CAR T-cell administration.
Study: 30938714
Drug: Conditioning chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning chemotherapy and 19-28z CAR T-cells.
Study: 30938874
Drug: Depressive symptoms,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depressive symptoms, self-esteem level, and types of treatment received
Study: 30939086
Drug: Hypnosis-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis-based group intervention combining self-care and hypnosis; details on dosage and duration not available.
Study: 30939489
Drug: EBR 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBR 50 mg plus GZR 50 mg once daily for 12 weeks
Study: 30939489
Drug: EBR 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBR 50 mg plus GZR 100 mg once daily for 12 weeks (control group)
Study: 30940770
Drug: Prednisolone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.5 mg/kg for 7 days)
Study: 30940999
Drug: Tdap (tetanus
Normalized name: Adacel Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine
Study: 30941094
Drug: Apomorphine, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine, dosage and duration not available
Study: 30941095
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) intramuscular injections
Study: 30942111
Drug: Drug adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug adherence assessment via toxicological urine analysis
Study: 30943124
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician or patient decision.
Study: 30943782
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of shoes equipped with the foot compression device (Footbeat™, AVEX, Grand Junction, CO, USA) for 4 weeks
Study: 30943913
Drug: Serum klotho
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum klotho levels < 518 pg/mL
Study: 30943928
Drug: Circulating tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating tumor cell (CTC) detection before therapy and after one course of preoperative FOLFOX
Study: 30946917
Drug: Newborn SCID
Normalized name: Vital E- Newborn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newborn SCID screening using quantification of T-cell receptor excision circles (TRECs) on Guthrie cards
Study: 30949435
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) in a waiting list control group (WLC)
Study: 30949674
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals treatment
Study: 30950636
Drug: Pirfenidone treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone treatment, timing of treatment initiation not specified.
Study: 30951840
Drug: One-time infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time infusion of donor-derived cytokine-induced killer (CIK) cells at a dose of 1 × 10^6 cells/kg.
Study: 30952529
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular hypertrophy (LVH) identified by LV mass index >46.7 g/m
Study: 30952619
Drug: Loss-of-function mutations
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loss-of-function mutations in epigenetic modulator genes (47%)
Study: 30952619
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor (AR) gene alterations (7%)
Study: 30953238
Drug: Afatinib (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (20, 30, 40, or 50 mg/day; physician decision)
Study: 30954717
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (chemotherapy with ifosfamide/doxorubicin)
Study: 30954717
Drug: Intermediate-/high-risk therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-/high-risk therapy (chemotherapy ± surgery ± radiotherapy)
Study: 30955188
Drug: Evocalcet 1-8
Normalized name: evocalcet
DrugBank: Evocalcet (DB12388)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Evocalcet 1-8 mg orally once daily for 32 weeks
Study: 30955420
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg cannabidiol
Study: 30955420
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg cannabidiol
Study: 30956800
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone application for daily breathlessness rating (0-10 NRS)
Study: 30956800
Drug: Daily and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily and weekly recall of breathlessness
Study: 30956961
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic (GA) 30 g/day for 12 weeks
Study: 30957229
Drug: Reinduction chemotherapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction chemotherapy plus bortezomib
Study: 30958020
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy (ICBT) course (8-week guided)
Study: 30958892
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off combined with intravenous cetuximab 250 mg/m²
Study: 30958892
Drug: Various dose
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various dose levels of regorafenib administered QD continuously or intermittently (3 weeks on/1 week off)
Study: 30959163
Drug: Pembrolizumab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (9 doses, i.v., 1 dose every 21 days starting on day +14 post-AHCT)
Study: 30959477
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2800 IE daily)
Study: 30962120
Drug: Low-sugar diet
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sugar diet (added sugars comprised 2.5% to 4.0% of daily calories)
Study: 30962222
Drug: SIRPαFc (TTI-621),
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIRPαFc (TTI-621), a novel CD47 decoy receptor, administered in clinical trial settings.
Study: 30962233
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment practices for PDN according to guidelines and local practices
Study: 30962330
Drug: Isavuconazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (single oral dose of isavuconazonium sulfate)
Study: 30962334
Drug: Imipenem-cilastatin (IMP-CS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (IMP-CS) at 15 mg/kg every 6 hours
Study: 30962334
Drug: Imipenem-cilastatin (IMP-CS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (IMP-CS) at 20 mg/kg every 6 hours
Study: 30962334
Drug: Imipenem-cilastatin (IMP-CS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (IMP-CS) at 25 mg/kg every 6 hours
Study: 30962681
Drug: Aclidinium bromide/formoterol
Normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 µg
Study: 30962681
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 µg
Study: 30962681
Drug: Aclidinium (AB)
DrugBank: Aclidinium (DB08897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium (AB) 400 µg
Study: 30962681
Drug: Formoterol (FF)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol (FF) 12 µg
Study: 30962697
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U100 plus insulin aspart
Study: 30962729
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg once daily)
Study: 30962963
Drug: Decitabine (5-aza-2'-deoxycytidine)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 10 mg/m2/day
Study: 30962963
Drug: Decitabine (5-aza-2'-deoxycytidine)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 15 mg/m2/day
Study: 30962963
Drug: Decitabine (5-aza-2'-deoxycytidine)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 20 mg/m2/day
Study: 30962963
Drug: Decitabine (5-aza-2'-deoxycytidine)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion
Study: 30963179
Drug: Feminizing hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feminizing hormone therapy (FHT)
Study: 30963212
Drug: Neoadjuvant nab-PTX
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant nab-PTX 260 mg/m2 with trastuzumab every 3 weeks for four cycles
Study: 30963506
Drug: Erenumab (140-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (140-mg subcutaneous dose)
Study: 30963506
Drug: Norgestimate/ethinyl estradiol-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestimate/ethinyl estradiol-containing oral contraceptive
Study: 30963691
Drug: Galunisertib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galunisertib (80 or 150 mg BID for 14 days per 28-day cycle)
Study: 30964436
Drug: e-message intervention
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-message intervention (3 to 4 electronic weekly messages)
Study: 30964439
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention consisting of monthly telephone calls for 6 months by a case manager and weekly, one-way informational text messages.